Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors

Rhea-AI Filing Summary

Zura Bio Limited reported that it has prepared an updated corporate presentation as of September 4, 2025. The presentation may be used at conferences and investor meetings to explain the company’s business and outlook.

The updated deck is filed as Exhibit 99.1 and is also available in the News & Events section of Zura Bio’s investor website. The company notes that this material is being furnished under a disclosure item for investor information and is not considered filed for liability purposes under U.S. securities laws or automatically incorporated into other SEC filings.

false 0001855644 0001855644 2025-09-04 2025-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Warrants [Member]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

September 4, 2025

Date of Report (Date of earliest event reported)

Zura Bio Limited

(Exact name of registrant as specified in its charter)

Cayman Islands		001-40598		98-1725736
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

 (Address of principal executive offices, including zip code)

(702) 757-6133

 (Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share		ZURA		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On September 4, 2025, Zura Bio Limited (“ZURA”, the “Company”) provided an updated corporate presentation that may be used in connection with presentations at conferences and investor meetings. The full text of the Company’s corporate presentation is filed as Exhibit 99.1 hereto, and incorporated herein by reference, and may also be accessed through the “News & Events” section of the Company’s website at investors.zurabio.com.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation, dated September 4, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZURA BIO LIMITED
Date: September 4, 2025	By:	/s/ Kim Davis
		Kim Davis
		Chief Operating Officer, Chief Legal Officer and Corporate Secretary

FAQ

What did Zura Bio Limited (ZURA) disclose in this 8-K?

Zura Bio Limited disclosed that it has prepared an updated corporate presentation, dated September 4, 2025, which may be used at conferences and investor meetings and is furnished as Exhibit 99.1.

Where can investors access Zura Bio’s updated September 4, 2025 corporate presentation?

Investors can access the updated corporate presentation as Exhibit 99.1 to this report and through the News & Events section of Zura Bio’s investor website at investors.zurabio.com.

Is the Zura Bio (ZURA) corporate presentation considered filed with the SEC?

No. The company states that the information under Item 7.01, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other SEC filings.

What is the purpose of Zura Bio furnishing this corporate presentation on Form 8-K?

The presentation is furnished to provide updated information that may be used in conferences and investor meetings, helping investors understand Zura Bio’s corporate story and related information.

Which exhibit contains the updated Zura Bio corporate presentation?

Exhibit 99.1 contains Zura Bio Limited’s updated corporate presentation dated September 4, 2025.

Who signed the Zura Bio 8-K for the updated corporate presentation?

The report was signed on behalf of Zura Bio Limited by Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary.